Increased teicoplanin doses are associated with improved serum levels but not drug toxicity
Philippa C Matthews1, Amy L Chue, David Wyllie
1Oxford Bone Infection Unit, Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7HE, UK; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, South Parks Road, Oxford OX1 3SY, UK.
Objective:
Teicoplanin is widely used for the treatment of severe gram-positive infection, aiming to achieve trough serum levels of 20-60 mg/L for patients with severe infection. A standard 400 mg daily dose is frequently associated with sub-therapeutic levels, and we have therefore changed our routine approach to 600 mg daily (following loading doses in each case). We set out to investigate the impact of this dose increase on drug levels and potential side-effects.
Methods:
We undertook a retrospective study of 549 consecutive adult Out-Patient Antimicrobial Treatment (OPAT) episodes treated with intravenous teicoplanin.
Results:
Therapeutic teicoplanin levels were more frequently achieved in patients treated with 600 mg compared to 400 mg daily (68% vs. 37% respectively, p < 0.0001), without an increased frequency of potentially toxic levels, defined as >60 mg/L (6% vs. 8% respectively, p = 0.4). There was no difference in the incidence of neutropaenia, eosinophilia, thrombocytopaenia, acute renal injury or treatment cessation in patients treated with the higher teicoplanin dose.
Conclusions:
In the majority of stable adult patients with normal renal function, we advocate a loading regimen (600 mg b.d. for two doses) followed by a 600 mg daily teicoplanin dose in order to achieve therapeutic trough levels.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Drug–Drug Interaction
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Therapeutic Index
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

